RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its wholly-owned unlisted Australian subsidiary ResolutionRx Ltd jointly announced that ResolutionRx has entered into a services agreement for clinical research and other related services with Melbourne, Australia-based contract research organization (CRO) iNGENu.
The companies said in a statement that under the agreement, iNGENu will act as a full-service CRO in support of ResolutionRx’s research and development program, which is developing a proprietary formulation of dronabinol for the treatment of obstructive sleep apnea and anorexia.
iNGENu will be responsible for conducting laboratory experiments to determine a final optimum dronabinol formulation, scaling up and manufacturing the chosen formulation for clinical use, preparing and submitting regulatory documents and designing and conducting clinical trials, including pharmacokinetic/pharmacodynamic, safety and pivotal efficacy studies, they said.
READ: RespireRx Pharmaceuticals' Australian subsidiary inks loan agreements to advance R&D for sleep apnea treatment
They noted that entry into this services agreement is one step in a series of transactions, some of which have been completed, some of which are in process, and others are anticipated to be completed in the near future.
Further details on the transactions can be found here.
iNGENu is a bespoke contract research organization focused on cannabinoid and psychedelic clinical research.
RespireRx is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options.
ResolutionRx is developing dronabinol, a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of obstructive sleep apnea.
Collectively, RespireRx and ResolutionRx are leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by the disruption of neuronal signalling.
Contact the author at emily.jarvie@proactiveinvestors.com
Find her on Twitter @emilyjjarvie